Precision BioSciences Current Ratio 2018-2021 | DTIL

Precision BioSciences current ratio from 2018 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Precision BioSciences Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.19B $0.04B 5.19
2021-03-31 $0.22B $0.06B 3.44
2020-12-31 $0.11B $0.04B 2.47
2020-09-30 $0.12B $0.04B 2.92
2020-06-30 $0.14B $0.03B 4.00
2020-03-31 $0.17B $0.02B 7.02
2019-12-31 $0.19B $0.03B 7.19
2019-09-30 $0.22B $0.02B 9.25
2019-06-30 $0.24B $0.02B 14.99
2019-03-31 $0.14B $0.07B 1.92
2018-12-31 $0.12B $0.01B 8.22
2018-09-30 $0.00B 0.00
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.06B $0.01B 6.99
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.578B $0.024B
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86